MEETING NEWS American Academy of Ophthalmology Meeting NEW ORLEANS — Novartis’ first-in-kind molecule brolucizumab achieved clinically relevant anatomic and visual acuity gains in patients with age-related macular degeneration with every-12-week dosing, according to a speaker. Two dosages of the single-chain antibody fragment VEGF inhibitor were compared with Eylea (aflibercept, Regeneron) in two phase 3 trials,… Read More »
Retinal Consultants of Arizona and the Retina Research Institute is dedicated to providing the most advanced, personalized patient care in Arizona. Our practice is at the forefront of implementing the latest technologies available for the diagnosis, management and treatment of retina and vitreous disease and conditions – all designed for the highest quality patient care… Read More »
Phoenix – December 8th, 2017 – On Monday, November 13th during the Society Presidents’ Recognition and Awards Session held in conjunction with AAO 2017 in New Orleans, Dr. Derek Y. Kunimoto was recognized for completing his participation in the Academy’s Leadership Development Program XIXI, Class of 2017. Dr. Kunimoto was among a select group of… Read More »
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness Brolucizumab, the first and only anti-VEGF to maintain a majority of patients on a 12-week treatment schedule immediately following loading phase in Phase III trials, met primary endpoint of non-inferiority vs aflibercept Significantly… Read More »
One Nonprofit is Working to Prevent This Avoidable Loss of Vision For People in Developing Countries By Beth Doane November is National Diabetes Month, and while so many of us know and understand complications related to the disease here in the US, there are many hidden costs to the disease that we don’t normally see. For example,… Read More »
Phoenix – October 15th, 2017 – Spectra Eye Institute – a leading, private outpatient surgical center dedicated to comprehensive ophthalmic surgical care – has opened its North Phoenix location inside the new Retinal Consultants of Arizona North Phoenix facility at Greenway and the I-17. The new 9,200 square foot surgical facility is set up for… Read More »
September 26, 2017 – Phoenix – Dr. Pravin U. Dugel, managing partner, Retinal Consultants of Arizona – one of the nation’s leading Retina & Vitreous academic, clinical research and patient treatment facilities – has been elected to the Orbis International Board of Directors. Orbis International is a global nonprofit dedicated to addressing the tragedy of… Read More »
Graybug Vision Initiates Phase 1/2 Trial of GB-102 for Wet Age-related Macular Degeneration – Novel Injectable Formulation for Potential Twice Per Year Treatment – Redwood City, CA – September 19, 2017 – Graybug Vision, Inc., a clinical-stage, venture-held pharmaceutical company committed to developing potentially transformative therapies for vision-threatening diseases including wet (neovascular) age-related macular degeneration… Read More »
When Dr. Pravin Dugel joined a small eye clinic in Phoenix in 1994, he had bigger dreams for the practice. “My inspiration was to see if I could build the best academic private practice center in the country,” said Dugel, who was 29 years old when he started his quest. He joined Retinal Consultants of Arizona… Read More »
Pravin U. Dugel, MD, Managing Partner, Retinal Consultants of Arizona; Clinical Professor, USC Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California; Physician Executive Director, Phoenix Eye Institute, Banner University Medical Center, Phoenix, Arizona describes the promising new drugs coming up the pipeline at the 17th Euretina Congress in Barcelona, Spain. These include next generation drugs… Read More »
